Decisions of the Unified Patent Court recorded under "Life sciences and pharma" in UPC Litigation Watch, the case law database maintained by Dhenne Avocats.
Decisions of the Unified Patent Court in pharmaceuticals, biotechnology and medical devices: validity and sufficiency, SPCs, generic and biosimilar launches, provisional measures and evidence.
121 decisions recorded
By decision of 25 November 2025, given in the joined appeals UPC_CoA_528/2024 and UPC_CoA_529/2024, the Court of Appeal set aside the decisions of the Munich Central Division of 16 July 2024, which had revoked Amgen’s EP 3 666 797 (antibodies against PCSK9)…
In an order of 16 October 2025, the judge-rapporteur of the Milan Central Division partly granted Herbert Smith Freehills Kramer's request for access to the file of the proceedings Insulet v EOFLOW (UPC_CFI_380/2024).
In a decision of 15 October 2025, the judge-rapporteur of the Milan Central Division assessed the recoverable costs payable by EOFLOW to Insulet following the decision on the merits of 22 July 2025 (proceedings UPC_CFI_773/2025 and UPC_CFI_774/2025, patent EP 4 201 327).
By an order of 25 August 2025 (UPC_CFI_688/2025, ORD_35448/2025), the judge-rapporteur of the Hamburg Local Division (Judge Johansson) refused to allow MED-EL's statement of claim in its infringement action concerning EP 4 074 373 to be served on Zhejiang Nurotron Biotechnology through…
By procedural order of 13 August 2025 (UPC_CFI_191/2025, App_34218/2025 and App_34202/2025), the judge rapporteur of The Hague Local Division partly granted the applications by Genevant Sciences and Arbutus Biopharma for an extension of time in their action for infringement of EP 2…
By a decision of 1 August 2025 (UPC_CFI_123/2024), the judge-rapporteur of the Hamburg Local Division fixed the costs recoverable by Samsung Bioepis NL from Alexion Pharmaceuticals for the provisional measures proceedings dismissed on 26 June 2024 (EP 3 167 888, Epysqli).
In a decision of 22 July 2025 (UPC_CFI_597/2024), given both on EOFLOW’s revocation action and on Insulet’s counterclaim for infringement, the Milan Central Division dismissed by default the revocation action against unitary patent EP 4 201 327, EOFLOW having refused to provide…
By decision of 19 June 2025, the Court of Appeal rejects as not allowable Alexion Pharmaceuticals’ application for rehearing of its order of 20 December 2024, which had upheld the refusal of provisional measures against nine Amgen group companies based on EP…
By a decision of 19 June 2025 (UPC_CoA_402/2024), the Court of Appeal rejected Alexion Pharmaceuticals' application for rehearing of its order of 20 December 2024, which had upheld the refusal of provisional measures against Samsung Bioepis (EP 3 167 888, treatment of…
On Insulet's application in its claim against EOFLOW for the costs of the provisional measures proceedings on EP 4 201 327, the judge rapporteur of the Milan Central Division partly protected the fee evidence filed.